Chemotherapeutic management of invasive bladder carcinoma

Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy.

Urologic oncology·2025

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.

ESMO open·2023

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.

ESMO open·2022

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

ESMO open·2021

Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.

European urology·2026

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

European urology·2026

Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine.

European urology·2026

PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study.

European urology·2026

EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

European urology·2026

UBA1 enhances phagocytosis by suppressing CD47 expression in small cell lung cancer.

Frontiers in oncology·2026

From the invasive front to organotropic pre-metastatic niches: spatial immune regulatory networks governing cholangiocarcinoma dissemination and metastasis-intercepting immunotherapy.

Frontiers in immunology·2026

[On a model of cisplatin-induced ototoxicity in Wistar rats].

Vestnik otorinolaringologii·2026

Comparative efficacy and safety of traditional Chinese medicine injections combined with chemotherapy for advanced non-small cell lung cancer: a Bayesian network meta-analysis.

Frontiers in immunology·2026

Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example.

Clinical and translational science·2026

Targeting cellular senescence mitigates chemotherapy-induced bone loss in young and aged mice.

GeroScience·2026

Related Experiment Videos

Chemotherapeutic management of invasive bladder carcinoma

Related Concept Videos

Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy.

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine.

PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study.

EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

UBA1 enhances phagocytosis by suppressing CD47 expression in small cell lung cancer.

From the invasive front to organotropic pre-metastatic niches: spatial immune regulatory networks governing cholangiocarcinoma dissemination and metastasis-intercepting immunotherapy.

[On a model of cisplatin-induced ototoxicity in Wistar rats].

Comparative efficacy and safety of traditional Chinese medicine injections combined with chemotherapy for advanced non-small cell lung cancer: a Bayesian network meta-analysis.

Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example.

Targeting cellular senescence mitigates chemotherapy-induced bone loss in young and aged mice.

Related Experiment Videos

Chemotherapeutic management of invasive bladder carcinoma

Related Concept Videos

Related Articles